512 related articles for article (PubMed ID: 8590836)
21. [Use of polymerase chain reaction (PCR) in oncohematology. Detection of minimal residual disease].
Kotliar N; Koziner B
Medicina (B Aires); 1995; 55(2):159-66. PubMed ID: 7565055
[TBL] [Abstract][Full Text] [Related]
22. Minimal residual disease in acute myelogenous leukemia with PML/RAR alpha or AML1/ETO mRNA and phenotypic analysis of possible T and natural killer cells in bone marrow.
Inokuchi K; Iwakiri R; Futaki M; Hanawa H; Tanosaki S; Nomura T; Dan K
Leuk Lymphoma; 1998 May; 29(5-6):553-61. PubMed ID: 9643569
[TBL] [Abstract][Full Text] [Related]
23. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
[TBL] [Abstract][Full Text] [Related]
24. tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease.
Breit TM; Beishuizen A; Ludwig WD; Mol EJ; Adriaansen HJ; van Wering ER; van Dongen JJ
Leukemia; 1993 Dec; 7(12):2004-11. PubMed ID: 8255100
[TBL] [Abstract][Full Text] [Related]
25. Rapid synthesis of hybrid RNA molecules associated with leukemia-specific chromosomal translocations.
Borkhardt A; Mitteis M; Brettreich S; Schlieben S; Hammermann J; Repp R; Kreuder J; Buchen U; Lampert F
Leukemia; 1995 Apr; 9(4):719-22. PubMed ID: 7723408
[TBL] [Abstract][Full Text] [Related]
26. Development and validation of a quantitative polymerase chain reaction assay to evaluate minimal residual disease for T-cell acute lymphoblastic leukemia and follicular lymphoma.
Hosler GA; Bash RO; Bai X; Jain V; Scheuermann RH
Am J Pathol; 1999 Apr; 154(4):1023-35. PubMed ID: 10233841
[TBL] [Abstract][Full Text] [Related]
27. A method to identify new molecular markers for assessing minimal residual disease in acute leukemia patients.
Jancuskova T; Plachy R; Stika J; Zemankova L; Hardekopf DW; Liehr T; Kosyakova N; Cmejla R; Zejskova L; Kozak T; Zak P; Zavrelova A; Havlikova P; Karas M; Junge A; Ramel C; Pekova S
Leuk Res; 2013 Oct; 37(10):1363-73. PubMed ID: 23870092
[TBL] [Abstract][Full Text] [Related]
28. The relation of oncogenesis and cytogenetics in leukemia and lymphoma.
Pearson M; Rowley JD
Annu Rev Med; 1985; 36():471-83. PubMed ID: 3888062
[TBL] [Abstract][Full Text] [Related]
29. Polymerase chain reaction in the diagnosis of chromosomal breakpoints.
Crisan D; Chen ST; Weil SC
Hematol Oncol Clin North Am; 1994 Aug; 8(4):725-50. PubMed ID: 7961288
[TBL] [Abstract][Full Text] [Related]
30. Identification of chromosomal breakpoints of cancer-specific translocations by rolling circle amplification and long-distance inverse PCR.
Thorsen J; Micci F; Heim S
Cancer Genet; 2011 Aug; 204(8):458-61. PubMed ID: 21962896
[TBL] [Abstract][Full Text] [Related]
31. Recurrent Cytogenetic Abnormalities in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia.
Ma ES
Methods Mol Biol; 2017; 1541():279-293. PubMed ID: 27910030
[TBL] [Abstract][Full Text] [Related]
32. Monitoring minimal residual disease using chromosomal translocations in childhood ALL.
Cazzaniga G; Rossi V; Biondi A
Best Pract Res Clin Haematol; 2002 Mar; 15(1):21-35. PubMed ID: 11987914
[TBL] [Abstract][Full Text] [Related]
33. [Clinical use of polymerase chain reaction in diagnosis and monitoring of malignant diseases].
Jäger U; Laczika K; Scholten C; Mitterbauer M; Novak M; Lechner K
Wien Klin Wochenschr; 1996; 108(20):634-9. PubMed ID: 9005678
[TBL] [Abstract][Full Text] [Related]
34. [The minimal residual disease (MRD) in hematological malignancies].
Yokota S; Okamoto T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):762-8. PubMed ID: 11432342
[TBL] [Abstract][Full Text] [Related]
35. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
Nunes V; Cazzaniga G; Biondi A
Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
[TBL] [Abstract][Full Text] [Related]
36. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
Madzo J; Zuna J; Muzíková K; Kalinová M; Krejcí O; Hrusák O; Otová B; Starý J; Trka J
Cancer; 2003 Jan; 97(1):105-13. PubMed ID: 12491511
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
[TBL] [Abstract][Full Text] [Related]
38. [Detection of BCR/ABL, MLL/AF4 and TEL/AML1 hybrid genes and monitoring of minimal residual disease in pediatric patients with acute lymphoblastic leukemia].
Trka J; Zuna J; Haskovec C; Brabencová A; Kalinová M; Muzíková K; Paukertová R; Hrusák O; Zemanová Z; Michalová K; Starý J
Cas Lek Cesk; 1999 Jan; 138(1):12-7. PubMed ID: 10953429
[TBL] [Abstract][Full Text] [Related]
39. Segmental jumping translocation in leukemia and lymphoma with a highly complex karyotype.
Tanaka K; Kamada N
Leuk Lymphoma; 1998 May; 29(5-6):563-75. PubMed ID: 9643570
[TBL] [Abstract][Full Text] [Related]
40. Follicular lymphoma: quantitation of minimal residual disease by PCR of the t(14;18) translocation.
Darby A; Gribben JG
Methods Mol Med; 2005; 115():315-31. PubMed ID: 15998976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
